Blujepa

Blujepa treats uncomplicated urinary tract infections in females and adolescents with more than 12 years and more than or equal to 40 kg. It’s an oral antibiotic in a new class that combats common UTI bacteria and tackles antibiotic resistance.

Molecule Details :

  • Molecule Name :

    Gepotidacin
  • Innovator :

    GLAXOSMITHKLINE LLC
  • Approval Date :

    25-Mar-25
  • NCE-1 Date :

    25-Mar-29
  • NCE Date :

    25-Mar-30
  • Dosage Form :

    Oral Tablet
  • Strength :

    EQ 750MG BASE
  • Therapeutic Category :

    Antibiotic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    52
  • 2026 :

    167
  • 2027 :

    253
  • 2028 :

    345
  • 2029 :

    427
  • 2030 :

    497
  • 2031 :

    567
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?